Crizotinib:a novel multi-targeted anti-tumor drug

Crizotinib is a novel oral multi-targeted tyrosine kinase inhibitor that inhibits c-Met and EML4-ALK fusion gene.Phase Ⅰ clinical recommended the drug dose of 250 mg,twice daily.EMLA-ALK is a fusion oncogene found in approximately 4%-7%of patients with non-small-cell lung cancer.Ⅰ/Ⅱ clinical trial showed that the one year survival rate of patients who harbor ALK translocation treated by crizotinib after several lines was 77%,and the two years survival rate was 64%.Currently,the crizotinib Ⅲ clinical trial is ongoing,and the FDA has proved crizotinib for the treatment of patients with advanced non-small-cell lung cancer whose tumors are ALK-positive.